| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 4
| Issue : 1 | Page : 56-61 |
|
|
Heme iron polypeptide (proferrin®-ES) versus iron saccharate complex (ferrosac) for treatment of iron deficiency anemia during pregnancy
Ibrahim A Abdelazim1, Mohannad Abu-Faza2, Assem A. M Elbiaa3, Hossam S Othman2, Dareen A Alsharif2, Walid Farok Elsawah4
1 Department of Obstetrics and Gynecology, Ain Shams University, Egypt; Department of Obstetrics and Gynecology, Ahmadi Hospital, Kuwait
2 Department of Obstetrics and Gynecology, Ahmadi Hospital, Kuwait
3 Department of Obstetrics and Gynecology, Ain Shams University, Egypt
4 Department of Critical Care and Emergency, Ahmadi Hospital, Kuwait
Correspondence Address:
Ibrahim A Abdelazim
Professor and Consultant of Obstetrics and Gynecology, Ain Shams University, Egypt and Ahmadi Hospital, Kuwait Oil Company (KOC), Ahmadi
 Source of Support: None, Conflict of Interest: None  | 6 |
DOI: 10.5530/ami.2017.4.11
|
|
|
Objectives: Anemia is one of the world's leading causes of considerable perinatal morbidity and mortality. This study designed to compare the efficacy and safety of Heme iron polypeptide (Proferrin®-ES) versus iron saccharate complex (Ferrosac) in treatment of iron deficiency anemia during pregnancy. Methods: Two hundred and sixty (260) pregnant women with hemoglobin level below 10 gm/dl due to iron deficiency anemia were included in this study and randomized to receive either; intravenous Iron Saccharate (IV group) or oral Proferrin®-ES (PO group) for correction of iron deficiency anemia during pregnancy. Treatment efficacy checked by comparing pre-treatment values of hemoglobin, serum ferritin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and reticulocytes count by the 3-months` post-treatment values. Results: The 3-months` post-treatment hemoglobin level increased compared to the pre-treatment level without any significant difference between the two studied groups (from 8.5 ± 3.5 to 11.3 ± 1.3 gm/dl in PO group and from 8.7 ± 2.5 to 11.7 ± 0.9 gm/dl in IV group). In addition; the 3-months` post-treatment ferritin level, increased compared to the pre-treatment level without any significant difference between the two studied groups (from 19.4 ± 4.9 to 118.8 ± 7.1 ug/l in PO group and from 15.3 ± 5.6 to 122.3 ± 6.4 ug/l in IV group). 1.6% (2/124) of the studied women developed gastrointestinal intolerance and upset with oral Proferrin®-ES (insignificant difference and excluded from the study) and no other side effects recorded with oral Proferrin®-ES. Conclusion: HIP (Proferrin®-ES) is an effective, safe, well tolerable oral iron preparation as well as intravenous iron saccharate complex for treatment of iron deficiency during pregnancy; it increases the hemoglobin and replaces the depleted iron store.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
